Therapeutic Effect Of High Dose Methotrexate Combined With Temozolomide On Primary Central Nervous System Lymphoma

Objective: This study through the Primary central nervous system lymphoma(Primary central nervous system lymphoma,PCNSL)in patients with contrast high-dose methotrexate(Hige dosed methylamine,HD-MTX)joint for mo thiazole amine(timozolomide,TMZ)and methotrexate alone two treatments,for mo thiazole amine combine high-dose methotrexate for the efficacy and safety of Primary central nervous system lymphoma.Methods: Collect 2010 January to June 2020 in the fourth hospital of hebei medical university PCNSL patients clinical data,according to the induction treatment is divided into the experimental group and control group,high-dose methotrexate + for mothiazole amine solution as the experimental group,patients receiving high-dose methotrexate patients as control group,the experimental group and control group in clinical curative effect,prognosis,and toxic effects of analysis.Results: A total of 41 patients were enrolled,including 24 in the experimental group and 17 in the control group.After 3 cycles of treatment,the radiographic response rate of the patients was assessed.The complete response rate of the experimental group was 67%,and that of the control group was 36%,P=0.028,which was statistically significant.The progressionfree survival of the experimental group was 14.08±10.50 months,and that of the control group was 13.65±12.68 months(P=0.906).The overall survival of the experimental group was 19.79 ±14.64 months.The overall survival time of the control group was 18.75±14.64 months(P=0.812).Conclusions: Compared with HD-MTX regimen,HD-MTX+TMZ regimen has a higher complete remission rate,no significant difference in prognosis between the two groups,and no increase in toxic reactions.